Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Hemostemix Inc. is a clinical-stage biotechnology company focused on developing autologous stem cell therapies for the treatment of cardiovascular and ischemic diseases. The company operates within the biotechnology and regenerative medicine industries, with a primary emphasis on addressing conditions with limited treatment options such as critical limb ischemia and other forms of peripheral arterial disease.
The company’s core product candidate is ACP-01, an autologous angiogenic cell therapy derived from a patient’s own blood. Hemostemix positions itself around personalized cell therapy, leveraging bone marrow–derived cells intended to promote vascular regeneration. The company was founded in 2003 and has evolved from early-stage research into a publicly listed clinical-stage developer, advancing its lead therapy through regulatory and clinical milestones primarily in North America.
Business Operations
Hemostemix’s operations are centered on research and clinical development rather than commercial production. Its single operating segment focuses on the development of ACP-01, which represents the company’s primary asset and anticipated future revenue driver pending regulatory approval. As a clinical-stage company, Hemostemix does not currently generate material commercial revenue and relies on equity financing and strategic funding to support operations.
Operational activities include clinical trial management, regulatory engagement, and proprietary cell-processing methodologies. The company conducts development activities primarily in Canada and the United States, working with contract research organizations and clinical partners. Public disclosures do not indicate the existence of material operating subsidiaries or revenue-generating joint ventures; data on formal long-term strategic partnerships is limited in publicly available filings.
Strategic Position & Investments
Hemostemix’s strategic direction is focused on advancing ACP-01 toward later-stage clinical development and potential commercialization, particularly for unmet needs in ischemic and cardiovascular conditions. Growth initiatives are centered on regulatory progress, clinical validation, and potential expansion of indications for its autologous cell therapy platform.
The company’s investment profile is concentrated rather than diversified, with capital allocation directed almost exclusively toward internal research and development. There is no verified public information confirming major acquisitions or ownership of notable portfolio companies. Engagement with emerging regenerative medicine technologies is limited to its proprietary cell therapy approach, and broader diversification into adjacent sectors has not been conclusively demonstrated in public disclosures.
Geographic Footprint
Hemostemix is headquartered in Canada, with its corporate base and primary regulatory jurisdiction tied to Canadian capital markets. Its operational footprint extends into the United States, where portions of its clinical research and regulatory strategy have been directed, reflecting the importance of the U.S. market for future commercialization.
Beyond North America, there is no verified evidence of significant operational presence, manufacturing infrastructure, or commercial activities in Europe, Asia, or other global regions. International influence remains largely prospective and dependent on future clinical and regulatory outcomes.
Leadership & Governance
Hemostemix is led by an executive team with experience in biotechnology commercialization and capital markets, with governance structured around advancing a single core therapeutic asset. Strategic leadership emphasizes disciplined capital management and regulatory progress in high-unmet-need indications.
Key executives include:
- Thomas Smeenk – Chief Executive Officer
- Paul J. O’Brien – Chief Financial Officer (data inconclusive based on available public sources)
- Fraser Henderson – Director (executive operational role data inconclusive based on available public sources)
Publicly available information on additional senior executives and their specific operational responsibilities is limited or inconsistent across filings and disclosures.